A Phase 3 Trial of Fianlimab (REGN3767, anti-Lag-3) + Cemiplimab versus Pembrolizumab in Patients with Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma (NCT05352672)
R3767-ONC-2011
This trial is No longer recruiting
Registration number NCT05352672
Program & service
This trial is being run with the Cancer service, and as part of the Medical Oncology program.
Trial phase
Phase 3
Trial participation type
This trial has been designed for the Clinical Research of a Drug.
Principal investigator
Associate Professor Andrew Haydon
More information
To find out more about this clinical trial, please review full details on the ANZCTR website.
View on ANZCTR